Compare Incyte Corporation (INCY) vs Oracle Corporation (ORCL) Price & Performance

Incyte CorporationTrade

Oracle CorporationTrade

Price performance (Past 24H)

Key statistics

Incyte Corporation vs Oracle Corporation — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Oracle Corporation trades at $127.6 (market cap $349.63B). The key difference: Oracle Corporation is far larger — about 15.1× Incyte Corporation's market cap, and Oracle Corporation pays a 1.65% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.

	INCY	ORCL
Market Cap	$23.11B	$349.63B
Sector	Health	Technology
52-Week High	$118.52	$328.33
52-Week Low	$67.38	$121.37
Enterprise Value	$19.13B	$478.88B
Dividend Yield	—	1.65%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Incyte Corporation

No Aura AI signal available yet.

Oracle Corporation

Oracle (ORCL) trades at $126.48, up 1.78% today, with a strong fundamental backdrop including revenue growth to $57.40B in 2025 and a net income margin of 25.37%. Recent quarters have consistently beaten EPS estimates, and analyst consensus is bullish with a $253.30 price target. Technicals show a bearish overall signal but with bullish oscillators, and the stock faces support near $125.

The outlook is positive given Oracle's AI infrastructure expansion and earnings momentum, but risks include high debt levels and competitive pressures. The stock offers growth potential if execution continues, yet investors should weigh valuation multiples against sector peers.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

INCY

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 5 hours agoBullish View details →

ORCL

Oracle shares hit key support and show oversold signs, hinting at a possible rebound soon.FXEmpire · 5 hours agoBullish Big tech's hidden debt hits $1.65T, raising investor risk amid AI investment surge.Finbold · 17 hours agoBearish Oracle shifts to AI hyperscale, faces credit downgrade but shows strong growth potential.Stuart Mooney · 1 day agoNeutral View details →

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

About Oracle Corporation

Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.